Dr. Daphne Koller of insitro on Digital Biology and Drug Discovery

The AI Health Podcast by Pranav Rajpurkar, Adriel Saporta, Oishi Banerjee, Marc Robbins

Jun 3, 202100:53:35Technology

This is the last episode of Season 1. Join us in the Fall for Season 2, and in the meantime, please take our brief survey! Dr. Daphne Koller is CEO and Founder of insitro, a machine-learning enabled drug discovery compan...

Related Episodes

Continue listening to more episodes from The AI Health Podcast.

Harvard's Dr. George Church on Aging Reversal, Woolly Mammoths, and the Future of Genomics

Jul 26, 2022 - 00:46:07

Dr. George Church is a Professor of Genetics at Harvard Medical School and a co-founder of multiple biote...

How Academia Can Make an Impact: University of Michigan's Dr. Karandeep Singh on Deployment and Evaluation

Jul 11, 2022 - 00:48:34

Karandeep Singh, MD, MMSc, is an Assistant Professor of Learning Health Sciences, Internal Medicine, Urol...

Immunai's Luis Voloch on Industrial-Scale Immunology

Jun 20, 2022 - 00:43:51

Luis Voloch is Co-Founder and Chief Technology Officer at Immunai, which is applying AI to immunology, ge...

Changemakers and Truth-Seekers: Johns Hopkins's Dr. Suchi Saria on Bayesian Health

Apr 4, 2022 - 00:42:58

Dr. Suchi Saria is the Founder and CEO of Bayesian Health, the John C. Malone Associate Professor of comp...

Medical (Incentives) Engineering: Harvard's Dr. Trishan Panch on Wellframe, Research and Entrepreneurship

Mar 21, 2022 - 00:45:09

Dr. Panch is a primary care physician, the Co-Founder of Wellframe, and an instructor at the Harvard T.H....

The Medical AI 2x2: GV’s Dr. Krishna Yeshwant on Market Positioning and Investing

Mar 7, 2022 - 00:40:50

Dr. Krishna Yeshwant is Managing Partner of GV. In addition to working with GV since its inception, he ha...

Like the Internet in 1999: Andreessen Horowitz‘s Julie Yoo on Investing and Modernizing Healthcare

Feb 21, 2022 - 00:46:08

Julie Yoo is a General Partner at Andreessen Horowitz where she leads investments in healthcare technolog...

Building a Bicycle: Obvious Ventures’ Nan Li on Investing and Platform Biology

Feb 7, 2022 - 00:49:17

Nan Li is Managing Director of Obvious Ventures, leading investments in computational biology visionaries...